Notice of Proposed Sale · 144

Alto Neuroscience Inc.

ANRONYSEEQUITYCurrent

Notice of Proposed Sale

Filed Sep 29, 2026Accepted Sep 29, 2026, 4:23 PM EDTFiling CIK 2009130Accession 0001950047-26-009858

View company →Permanent SEC source ↗

Structured filing — 144

primary_doc.xml

Open full document ↗

Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.

Proposed-sale notice

Issuer: ALTO NEUROSCIENCE INC
Issuer CIK: 0001999480
SEC file number: 001-41944
Phone: 6502000412
Person for whose account securities are to be sold: NICHOLAS SMITH
Relationships to issuer: Officer
Street: 650 Castro Street, Suite 450
City: Mountain View
State / country code: CA
Postal code: 94041

Securities proposed for sale

Securities proposed for sale · 1 reported row
Security	Proposed units	Aggregate market value	Units outstanding	Approximate sale date	Exchange	Broker / market maker
Common	134,886	3,596,060.76	39,242,104	09/29/2026	NYSE	Morgan Stanley Smith Barney LLC Executive Financial Services

Broker / market maker — proposed row 1, entry 1

Name: Morgan Stanley Smith Barney LLC Executive Financial Services
Street: 1 New York Plaza
Street (continued): 8th Floor
City: New York
State / country code: NY
Postal code: 10004

Acquisition of securities to be sold

Acquisition of securities to be sold · 1 reported row
Security	Acquired	Nature of acquisition	Acquired from	Amount acquired	Gift transaction	Payment date	Nature of payment
Common	09/29/2026	Exercise of Stock Options	Issuer	134,886	N	09/29/2026	Cash

Prior-sale reporting

Nothing to report for the preceding three months: Y

Remarks

The securities to be sold were and will be received upon the exercise of stock options over the next three months. The dates of acquisition and payment were and will be the dates of exercise/sale.

Notice signature

Notice date: 09/29/2026
Signed: /s/ Nicholas Smith
Plan adoption dates: 06/30/2026

Company context

Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Alto’s Precision Psychiatry Platform™ measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to better identify which patients are more likely to respond to Alto product candidates. Alto’s clinical-stage pipeline includes novel drug candidates in bipolar depression, major depressive disorder, treatment resistant depression, schizophrenia, and other mental health conditions. For more information, visit www.altoneuroscience.com or follow Alto on X.

Current securities

ANRONYSE · EQUITY · Current

Get the free weekly BCS email.